Coherent
COHERENT CORP.
Key figures
Period Jul 2025 to Jun 2026ConsolidatedU.S. GAAP
RevenueDisclosed
US$7.1B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
59.6%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★★★★★position among all companies
21.0%
Capital efficiency
★★☆☆☆position among all companies
7.4%
Revenue and profit
Performance, financial position and capital allocation
Coherent
Recent performance trends
Coherent
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$3.3 billion | US$5.2 billion | US$4.7 billion | US$5.8 billion | US$7.1 billion |
| Operating income | US$0.4 billion | US$-37.12 million | US$96.12 million | Could not be retrieved | Could not be retrieved |
| Net income | US$0.2 billion | US$-0.3 billion | US$-0.2 billion | US$49.36 million | US$0.8 billion |
| Total assets | US$7.8 billion | US$13.7 billion | US$14.5 billion | US$14.9 billion | US$18.3 billion |
| Shareholders' equity | US$3.6 billion | US$5.0 billion | US$5.2 billion | US$5.6 billion | US$10.9 billion |
| Net cash provided by (used in) operating activities | US$0.4 billion | US$0.6 billion | US$0.5 billion | US$0.6 billion | US$79.51 million |
| Net cash provided by (used in) investing activities | US$-0.3 billion | US$-5.9 billion | US$-0.4 billion | US$-0.4 billion | US$-1.4 billion |
| Net cash provided by (used in) financing activities | US$0.9 billion | US$3.6 billion | US$0.8 billion | US$-0.5 billion | US$1.5 billion |
| Cash and cash equivalents | US$2.6 billion | US$0.8 billion | US$0.9 billion | US$0.9 billion | US$1.2 billion |
Revenue scale in the same industry
Coherent
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 15 companies
- 19 AmetekFY Dec 2025 US$7.4B
- 20 GarminFY Dec 2025 US$7.2B
- 21 CoherentThis companyFY Jun 2026 US$7.1B
- 22 Agilent TechnologiesFY Oct 2025 US$6.9B
- 23 AvantorFY Dec 2025 US$6.6B
- … 20 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$1.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$1.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$79.51 million | Consolidated | Disclosed |
| Depreciation and amortization | US$0.5 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$11.2 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.3 billion | Consolidated | Disclosed |
| Net assets | US$10.9 billion | Consolidated | Disclosed |
| Net sales | US$7.1 billion | Consolidated | Disclosed |
| Net income | US$0.8 billion | Consolidated | Disclosed |
| Total assets | US$18.3 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 59.6% | Consolidated | Calculated |
| Net margin | 11.3% | Consolidated | Calculated |
| Return on equity | 7.4% | Consolidated | Calculated |